-Business Standard It is an annual review of the state of IPR protection and enforcement of America's trading partners Notwithstanding the recent bonhomie of sorts between Prime Minister Narendra Modi and US President Barack Obama, India's status as ‘Priority Watch List' country for having an alleged weak intellectual property rights (IPR) and patents regime is unlikely to see any improvement in the US' 2015 Special 301 Report. The 2015 Special 301 Report is...

-The Hindu Business Line Seek clarification on US trade representative's testimony that India has committed to address IP issues that concern America Mumbai: Has India informally agreed to make changes in its Intellectual Property Rights regime on the basis of US concerns? A sizeable section of the Indian pharmaceutical industry and some pro-health groups are worried that it has, following US Trade Representative Ambassador Michael Froman's testimony to the Senate Committee on...

-The Times of India NEW DELHI: Leading US health groups including AVAC, Oxfam America, amfAR, Health Global Access Project (GAP), TAG (Treatment Action Group)and others have written to Barack Obama urging him to support India in providing "high-quality, low-cost generic medicines essential for health care around the world". This comes in the wake of the two nations agreeing to enhance engagement on IPR at the latest bilateral talks. Sunday's joint statement after...

-The Telegraph New Delhi: Health and patients' rights groups have called on the government to resist American pressure that they claimed was aimed at weakening safeguards in India's patent laws that allow drug companies to sell inexpensive generic medicine. Health activists representing patients' rights said they were concerned that bilateral talks on intellectual property rights, to feature during US President Barack Obama's visit to India beginning this weekend, may be rigged against...

-The Times of India NEW DELHI: The government may negotiate prices of patented medicines with their manufacturers before allowing pharmaceutical companies to launch them in India. The move, a first of its kind, is also likely to be applied on patented drugs that are already being sold in the country, an official source said. An inter-ministerial committee, evaluating the mechanism to negotiate prices of patented medicines, has recently sought detailed information about...